How Smart Biotechs Scale Organizations Fast and Maximize Value

April 13, 2018

According to a recent study from Deloitte, it is estimated that bringing a new drug to market can cost almost $2 billion. While the costs to develop assets are rising, the value per asset continues to decline with pricing pressures coming from every direction and increased competition in the market from expiring patents and less innovative products entering the market.  This means every month spent on development could mean millions of dollars in unrealized revenue - revenue that is key to achieving an attractive ROI. 

However, there is a silver lining as that same Deloitte study highlights that smaller firms outperform larger peers... by nearly 400%. Large pharmaceutical companies project a 3.2% return, while smaller firms project nearly 12%. 

How do these firms outperform their larger predecessors?  Many are winning by not just innovating their product, but the most sophisticated firms are developing organizations built for speed, agility, and cost-efficiencies across the development lifecycle to be successful.

To learn more about how to build your biotech organization to scale quickly and maximize value, listen in above to industry leaders as they share processes and tools that will help you develop the right team to accelerate your development and go-to-market strategies in order to get your assets in the hands of patients that need them as fast as possible.

You'll leave with an understanding of who the right people are to have on your team, where you need them and when to scale your team effectively to maximize efficiency, based on a combined 50+ years of experience getting drugs to market. Learn more about the speakers below, and be sure to tune in to the free webinar above.

About Patricia Bradley: Patricia is an innovative commercial executive with 20+ years of biopharmaceutical experience - primarily focused in rare and chronic diseases.  Throughout her sales and marketing career she has advanced through multiple leadership roles at Novo Nordisk including the development of new organizations and businesses focused on building innovative, go-to-market strategies and approaches.  She has a proven track record creating new field sales, marketing and commercial operations teams that drive superior performance over traditional models. Her organizations have achieved results through market responsiveness, resilience, flexibility, robust processes (Continuous Quality Improvement) and market trend insights. 

About Joseph Lamendola, Ph.D.: Dr. Lamendola is the SVP of YourEncore's biopharma practice and the former US VP of Regulatory Sciences for Bristol-Myers Squibb.  Over a 25 year regulatory career, Dr. Lamendola is responsible for 20+ approvals across 10+ therapeutic areas.  With hundreds of agency interactions under his belt, Joe provides clients with the insights, relationships, and credibility needed to bring drugs to patients quicker.

Previous Article
The Path to Patient Centricity: Part I
The Path to Patient Centricity: Part I

Learn more from Regina Shanklin on how seeing things from the patient’s point-of-view will help you meet th...

Next Content Item
Virtual Pharma R&D: Open for Business
Virtual Pharma R&D: Open for Business